ClinicalTrials.gg
RecruitingNCT06533358Updated Aug 1, 2024

A Clinical Study of MT1002 in Subjects With Acute Coronary Syndrome Undergoing PCI

A Phase 2 interventional study of MT1002 Injection in Acute Coronary Syndrome, sponsored by Shaanxi Micot Technology Limited Company. Recruiting at 2 sites in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-08-01.

Sponsored by Shaanxi Micot Technology Limited Company · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Registered 4 months after the study started (first participant enrolled Feb 2024, registered Jul 2024).
  • Started Feb 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 185 studies in Acute Coronary Syndrome with a site in China — 55 open to participants now, 63 under way, 3 of them phase 3. Acute Coronary Syndrome · China.

Planned enrollment
112th of 115
20 · median 499
Started
2024
with 17 others
Phase 2
Only one
of the 185
Primary completion
2024-12
later than 10 of 62 live
Registered
148th of 185
by date

Among the 185 studies in Acute Coronary Syndrome with a site in China, this one is the 112th largest by planned enrollment of the 115 interventional ones that give a count, is one of 18 that started in 2024, is the only one in phase 2, reaches primary completion later than 10 of the 62 other live ones, and was the 148th registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

55 of the 185 studies in Acute Coronary Syndrome with a site in China are open now. Recruiting first, the newest first:

50 more — sign in →

All 55 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 185 studies in Acute Coronary Syndrome with a site in China, or all of them as a file.
02

Study summary

An Open-label, Sequential Dose Escalation/De-escalation Clinical Trial of MT1002 in Subjects With Acute Coronary Syndrome Undergoing PCI.

Read the detailed description

MT1002 is a novel 32-amino acid synthetic peptide aimed to combine molecular functions of both a direct thrombin inhibitor and a platelet glycoprotein IIb/IIIa receptor antagonist, indicated for use as an antithrombotic and anticoagulant in patients with ACS and in patients undergoing PCI.

This study is an Open-label, sequential dose escalation/de-escalation clinical trial of MT1002 in subjects with acute coronary syndrome undergoing PCI. First dose cohort is 0.60 mg/kg (initial loading dose, intravenous bolus) + 1.2 mg/kg/h*4 h (maintenance dose, intravenous infusion). The Safety Review Committee makes decisions on subsequent dose adjustments. Dose escalation/de-escalation and stopping rules have been put in place to ensure the safety of the patients in this study.

03

Conditions studied

  • Acute Coronary Syndrome
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female aged 18-85 years old (both 18 and 85 years old)
  2. Diagnosis of acute coronary syndrome (ACS)
  3. Subjects who will undergo PCI during hospitalization
  4. Able to understand and willing to sign written prior to undertaking any study-related activities
  5. Females of must have a negative pregnancy test result prior to enrollment or be for at least 1 year, or permanently sterilized for ≥ 6 weeks. For women of childbearing potential and men with female partners of childbearing potential, effective must be used if they are sexually active from the time of informed consent until 90 days after MT1002 administration

Exclusion criteria

Exclusion Criteria:

  1. cardiogenic shock, or cardiopulmonary resuscitation (CPR)
  2. Suspicious aortic dissection, pericarditis, endocarditis
  3. Has any history of intracranial hemorrhage or structural abnormalities
  4. , stroke within 6 months
  5. History of gastrointestinal or genitourinary bleeding within 1 month
  6. Major surgery within 1 month
  7. The following surgeries are planned within 1 month of enrollment: CABG, valve surgery, or other invasive procedures
  8. Long-term treatment with non-steroidal anti-inflammatory drugs (except aspirin), cyclooxygenase (COX)-2 inhibitors, within 1 month prior to screening
  9. Prior (within 7 days prior to enrollment) or planned use of thrombolytic agents, bivalirudin, or fondaparinux. 12 hours before enrollment, unfractionated heparin or low molecular weight heparin was injected subcutaneously.
  10. Use of coumarin derivatives and/or factor Xa inhibitors in the past 7 days
  11. Anticipated need for oral anticoagulants within 3 days of dosing
  12. Severe uncontrolled hypertension persists even within 24 hours of adequate treatment
  13. According to the judgment of the investigator, the subject has a high risk of bleeding, such as active bleeding, bleeding tendency, coagulation disorders, etc
  14. Known associated hematologic abnormalities
  15. Known to have a or comorbid other disease that may lead to protocol non-adherence with a of \< 1 year
  16. Known severe liver disease
  17. Known and , screening serology positive, except for the low viral replication phase.
  18. Known chronic kidney disease
  19. Known allergy or intolerance to aspirin, clopidogrel, ticagrelor, prasugrel, bivalirudin, unfractionated heparin, P2Y12 antagonists, or contrast agents.
  20. Weight: male subjects should not be less than 50.0kg, female subjects should not be less than 45.0kg, and within the range of 18.0\~30.0kg/m2 (including boundary values)
  21. Subjects who have previously used MT1002.
  22. Unable to fully cooperate with the study protocol.
  23. Has any other medical or psychiatric illness that, in the opinion of the investigator, precludes participation in the study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    MT1002 Injection

    MT1002 is infused once only, once for 4h

    Drug: MT1002 Injection

Interventions

  • DrugMT1002Studies of MT1002MT1002 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    MT1002 is infused once only, once for 4h. MT1002 is for subjects with acute coronary syndrome undergoing PCI

    Also known as: No other name

06

What researchers measure

Primary outcomes

  1. percentage of subjects who achieved target ACT (200-300 s)

    percentage of subjects achieving target ACT (200-300 s) among subjects receiving MT1002 (not switching to standard care) pre/intraoperatively and after successful PCI

    Time frame: Day 1, 24 hours (Day 2) to Day 30±2 after intravenous injection on Day 1

  2. Major bleeding events

    Adverse events (AEs): Major bleeding events (Bleeding Academic Research Consortium \[BARC\] type 3-5)

    Time frame: Day 1 to end of follow-up period (Day 30±2)

07

Study locations

2 of 2 sites recruiting
  • Beijing Anzhen Hospital Affiliated to Capital Medical University
    Beijing, Beijing 100029, China
    Recruiting
  • Xianyang Hospital, Yan'an University
    Xi'an, Shaanxi 712000, China
    Recruiting
    • Qiufang Lian · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Dec 2024, 10 months after the start.

Of 30 phase 2 interventional studies under Acute Coronary Syndrome, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's planned 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2024
First posted
Aug 1, 2024
StartActual
Feb 27, 2024
Primary completionEst.
Dec 2024
CompletionEst.
Jul 2025
Last update
Aug 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06533358
Lead sponsor
Shaanxi Micot Technology Limited Company
Responsible party
Sponsor
First posted
Aug 1, 2024
Start date
Feb 27, 2024
Primary completion
Dec 2024 (estimated)
Completion
Jul 2025 (estimated)
Last update
Aug 1, 2024

Study contacts

Changsheng Ma, Medical phd
Contact
chshma@vip.sina.com
13501373114
NA NA NA
Contact
Changsheng Ma, Medical phd
principal investigator · Beijing Anzhen Hospital Affiliated to Capital Medical University

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MT1002

Start the discussion